Tibor Kovacsovics
Overview
Explore the profile of Tibor Kovacsovics including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1470
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Issa G, Aldoss I, Thirman M, DiPersio J, Arellano M, Blachly J, et al.
J Clin Oncol
. 2024 Aug;
43(1):75-84.
PMID: 39121437
Purpose: Revumenib, an oral, small molecule inhibitor of the menin-lysine methyltransferase 2A (KMT2A) interaction, showed promising efficacy and safety in a phase I study of heavily pretreated patients with -rearranged...
2.
Hoff F, Blum W, Huang Y, Welkie R, Swords R, Traer E, et al.
Blood Adv
. 2024 Aug;
8(20):5297-5305.
PMID: 39110987
Although the 2022 European LeukemiaNet (ELN) acute myeloid leukemia (AML) risk classification reliably predicts outcomes in younger patients treated with intensive chemotherapy, it is unclear whether it applies to adults ...
3.
Bewersdorf J, Shallis R, Sharon E, Park S, Ramaswamy R, Roe C, et al.
Ann Hematol
. 2023 Nov;
103(1):105-116.
PMID: 38036712
Patients with myelodysplastic syndromes/neoplasms (MDS) or acute myeloid leukemia (AML) with hypomethylating agent failure have a poor prognosis. Myeloid-derived suppressor cells (MDSCs) can contribute to MDS progression and mediate resistance...
4.
Cai S, Huang Y, Lance J, Mao H, Dunbar A, McNulty S, et al.
Blood Adv
. 2023 Oct;
8(2):429-440.
PMID: 37871309
Enasidenib (ENA) is an inhibitor of isocitrate dehydrogenase 2 (IDH2) approved for the treatment of patients with IDH2-mutant relapsed/refractory acute myeloid leukemia (AML). In this phase 2/1b Beat AML substudy,...
5.
Borate U, Yang F, Press R, Ruppert A, Jones D, Caruthers S, et al.
Blood Adv
. 2023 Jul;
7(20):6048-6054.
PMID: 37459200
Next-generation sequencing (NGS) to identify pathogenic mutations is an integral part of acute myeloid leukemia (AML) therapeutic decision-making. The concordance in identifying pathogenic mutations among different NGS platforms at different...
6.
Lee J, Wagner C, Prelewicz S, Kurish H, Walchack R, Cenin D, et al.
Haematologica
. 2023 Jun;
108(12):3460-3463.
PMID: 37345485
No abstract available.
7.
Duong V, Ruppert A, Mims A, Borate U, Stein E, Baer M, et al.
Cancer
. 2023 Apr;
129(15):2308-2320.
PMID: 37078412
Background: Patients with acute myeloid leukemia (AML) who have tumor protein p53 (TP53) mutations or a complex karyotype have a poor prognosis, and hypomethylating agents are often used. The authors...
8.
Saliba A, Kaufmann S, Stein E, Patel P, Baer M, Stock W, et al.
Blood Adv
. 2022 Oct;
7(11):2360-2363.
PMID: 36315007
No abstract available.
9.
Jonas B, DiNardo C, Fracchiolla N, Pristupa A, Ishizawa K, Jin J, et al.
Am J Hematol
. 2022 Sep;
97(11):E422-E425.
PMID: 36053878
No abstract available.
10.
Hoshina Y, Galli J, Wong K, Kovacsovics T, Steinbach M, Salzman K, et al.
Neurol Neuroimmunol Neuroinflamm
. 2022 Aug;
9(6).
PMID: 36028311
Background And Objectives: The relationship between autologous hematopoietic stem cell transplant (aHSCT) for multiple myeloma (MM) and anti-GABA receptor (GABAR) encephalitis is unknown. We aimed to describe the clinical features,...